ICU Medical stock faces recall scrutiny after Q2 results
ICU Medical (ICUI) stock is under scrutiny due to two Class II recalls affecting CADD reservoirs and Plum administration sets, impacting over 185,000 and 163 million units respectively. This comes as the company reported Q2 2026 revenue of $551.7 million, exceeding consensus estimates of $533.4 million, and updated its fiscal 2026 EPS guidance to $8.60-$9.00. Analysts maintain a "Moderate Buy" rating with an average 12-month price target of $192.80, despite the stock trading below its 52-week high amid concerns over product reliability and recall execution.
(ICUI) Movement Within Algorithmic Entry Frameworks
Icu Medical Inc. (NASDAQ: ICUI) is exhibiting mixed sentiment with weak near-term outlook but strong long-term potential, according to algorithmic analysis. The article outlines various trading strategies including long, breakout, and short positions with specific entry, target, and stop-loss levels. It also provides a multi-timeframe signal analysis indicating support and resistance levels.
Analysts Offer Insights on NA Companies: Hexcel (HXL), International Paper Co (IP) and ICU Medical (ICUI)
This article highlights bullish sentiments from analysts on three North American companies: Hexcel (HXL), International Paper Co (IP), and ICU Medical (ICUI). RBC Capital maintained a Buy rating on Hexcel with a $115 price target, while J.P. Morgan reiterated a Buy on International Paper Co with a $62 price target, and Piper Sandler reaffirmed a Buy rating on ICU Medical with a $195 price target. The analysis includes details on each analyst's performance and the overall consensus rating for each stock.
ICU Medical, Inc. (ICUI) Stock forecasts
Argus has issued a stock forecast for ICU Medical, Inc. (ICUI), raising its target price to $169.00 from a current price of $166.02. The report, dated September 23, 2026, describes ICU Medical as a California-based pure-play infusion therapy company.
A Look at ICU Medical Inc (ICUI) After 3.7% Gain -- GF Value $121.40 vs Price $160.98
ICU Medical Inc (ICUI) shares recently rose 3.7% to $160.98, significantly above its GF Value™ estimate of $121.40, indicating it is "Significantly Overvalued." The company has a strong GF Score™ of 83/100, driven by profitability and momentum, but its valuation rank is weak, and insiders have sold $8.3 million in shares with no buying activity, suggesting caution for investors.
Otsuka ICU Medical Recalls One Lot of IV Saline After Potassium Chloride Bag Found Inside Saline Overwrap
Otsuka ICU Medical LLC has issued a recall for one lot of 0.9% Sodium Chloride Injection, USP (saline) after a customer discovered a bag of concentrated potassium chloride inside a saline-labeled overwrap. The recall, affecting lot 1042188, targets hospitals and clinics, though no adverse events have been reported. The primary safeguard against accidental administration is the clear labeling on the inner potassium chloride bag, requiring healthcare professionals to check before use.
ICU Medical CFO Sells 6,381 Shares for $1.1 Million
ICU Medical's CFO, Brian Michael Bonnell, sold 6,381 shares of common stock for $1.1 million on September 1, 2026, as part of a pre-established Rule 10b5-1 trading plan. Despite the sale, Bonnell retains 56,062 shares valued at approximately $9.5 million, indicating continued confidence in the company. The sale is considered routine and not a cause for alarm, especially given ICU Medical's recent positive financial performance and stock growth.
Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection
Otsuka ICU Medical LLC is initiating a voluntary nationwide recall of one lot of 0.9% Sodium Chloride Injection, USP, 100 mL due to a potential product mix-up. The recall stems from a customer complaint where a 10 mEq Potassium Chloride Injection 100 mL bag was found inside an overwrap labeled for Sodium Chloride Injection. Inadvertent injection of highly concentrated potassium chloride carries a reasonable probability of adverse events, including neuromuscular dysfunction, cardiac dysrhythmias, and potentially fatal outcomes, especially for vulnerable patient populations.
ICU Medical at Wells Fargo conference: focus shifts to cash returns
At the Wells Fargo 21st Annual Healthcare Conference, ICU Medical (ICUI) outlined a strategy focused on portfolio discipline, operational improvements, and a future shift towards shareholder returns through buybacks and dividends. The company aims to reach a 2x leverage ratio by the end of 2024, after which it plans to prioritize returning capital to shareholders. While IV systems and consumables show mid-single-digit growth, the Vital Care segment continues to be a drag, and management seeks to improve gross margins and cash flow conversion.
ICU Medical at Wells Fargo conference: focus shifts to cash returns
ICU Medical (ICUI) presented at the Wells Fargo 21st Annual Healthcare Conference, outlining a strategic shift towards shareholder returns after years of building an integrated infusion business. The company expects to achieve a 2x leverage ratio by the end of 2024, after which it plans to prioritize buybacks and dividends. While core businesses like IV systems and consumables are performing well, the Vital Care segment remains a drag, and the company is not planning increased investment in it, opting to operate it until better options emerge.
ICU Medical Insider Sold Shares Worth $1,116,675, According to a Recent SEC Filing
An insider at ICU Medical, Inc. sold shares worth $1,116,675, as disclosed in a recent SEC filing. This transaction follows other insider share sales from the company, including one on August 31st for $1,608,143. ICU Medical specializes in medical products for infusion therapy, vascular access, and vital care.
Icu medical chief financial officer Brian Bonnell sells $1.1 million in stock
ICU Medical Inc.'s CFO, Brian Bonnell, sold 6,381 shares worth $1,116,675 on September 1, 2026, pursuant to a pre-arranged trading plan. Despite the sale, ICU Medical shares have risen 34% over the past year and are considered undervalued by InvestingPro, with analysts revising earnings upwards. The company also recently reported strong Q2 earnings, raised full-year guidance, and received a credit rating upgrade from S&P Global Ratings.
ICUI: ICU Medical, Inc. Latest Stock Price, Analysis, News and Trading Ideas
This article provides an overview of ICU Medical, Inc. (ICUI), including its current stock price ($161.60), market capitalization ($3.88B), and key financial metrics. It highlights the company's focus on innovative medical products for infusion therapy and critical care, and mentions recent news such as CFO stock sales and an analyst's market sentiment. The company was founded in 1984 and is headquartered in San Clemente, CA.
ICU Medical Insider Sold Shares Worth $1,608,143, According to a Recent SEC Filing
An insider at ICU Medical, Inc. sold shares valued at $1,608,143, according to a recent SEC filing. This follows previous insider share sales reported in August, including one worth $401,209 and another for $1,633,404. The company recently announced Q2 2026 earnings that exceeded estimates and revised its full-year 2026 guidance upwards.
ICUI Price History for I C U Medical Stock
This Barchart.com page provides the price history for I C U Medical Inc (ICUI), offering various data views such as daily prices, latest trades, and corporate actions. It details 52-week key points, including high, low, and Fibonacci levels, and tracks new high and low occurrences over different periods. The article also explains the functionalities available to different membership tiers, such as downloading historical data and customizing data views.
ICU Medical rating upgraded by S&P on stronger credit metrics
S&P Global Ratings has upgraded ICU Medical Inc. to 'BB' from 'BB-', citing the company's strengthened credit metrics and solid operating performance. This upgrade is primarily due to a significant reduction in adjusted leverage to 3.1x as of Q2 2026 and robust free operating cash flow generation. ICU Medical achieved this by using proceeds from a 2025 divestiture and additional operating cash flow to repay debt, with S&P projecting continued deleveraging and mid-single-digit revenue growth through 2027.
Otsuka ICU Medical breaks ground on 500,000 square foot Austin site expansion
Otsuka ICU Medical has commenced construction on a 500,000-square-foot expansion of its North Austin campus, a $500 million project expected to double the existing facility's size by 2030. This expansion aims to enhance the reliability and resilience of the U.S. IV products supply chain, a critical need highlighted by past shortages. The joint venture plans further life sciences investment in the Austin area and seeks to strengthen its manufacturing footprint, expand non-DEHP capabilities, and introduce innovation.
ICU Medical DevOps Salaries in Logan, UT
The average ICU Medical DevOps in Logan, UT earns an estimated $122,305 annually, including a base salary of $108,003 and a $14,303 bonus, which is higher than the US average for DevOps. Salaries can range from $46,880 to $275,000, and the Engineering Department at ICU Medical earns more than the Marketing Department. Most DevOps employees at ICU Medical feel they are not fairly compensated, but the majority are satisfied with their benefits.
Madison Asset Management LLC Takes $2.65 Million Position in ICU Medical, Inc. $ICUI
Madison Asset Management LLC has acquired a new position in ICU Medical, Inc. (NASDAQ:ICUI), purchasing 18,088 shares valued at approximately $2.65 million. This comes as institutional investors collectively own 96.1% of the company. Analysts maintain a positive outlook with a "Moderate Buy" rating and an average price target of $192.80, while the company recently surpassed earnings expectations but saw significant insider selling.
ICU Medical HR Specialist Salaries in Auburn, AL
The average ICU Medical HR Specialist in Auburn, AL earns an estimated $75,330 annually, which is slightly higher than the US average for this role. The HR Department at ICU Medical in Auburn, AL, also earns more on average than the IT Department. Most HR Specialists at ICU Medical believe their compensation is not fair, but a majority are satisfied with their benefits.
Upgraded 2026 Earnings Guidance After Softer Q2 Might Change The Case For Investing In ICU Medical (ICUI)
ICU Medical (ICUI) reported softer Q2 2026 earnings but saw a significant increase in six-month net income and raised its full-year 2026 GAAP net income and EPS guidance. This upgraded guidance suggests improving profitability and operational efficiencies, despite ongoing challenges related to product recalls and integration costs. The company's investment narrative centers on its role as a core provider of infusion systems, with a long-term forecast of $2.5 billion revenue and $173.2 million earnings by 2029, and a fair value estimate of $191.50 per share.
Upgraded 2026 Earnings Guidance After Softer Q2 Might Change The Case For Investing In ICU Medical (ICUI)
ICU Medical, Inc. reported softer Q2 2026 earnings, with sales of US$551.68 million and net income of US$19.09 million, but their six-month net income more than doubled. Despite the softer quarter, management upgraded its full-year 2026 GAAP net income guidance to US$73 million–US$83 million and diluted EPS to US$2.89–US$3.29, suggesting improving profitability. This positive guidance reinforces the company's investment narrative, focusing on operational efficiencies and integration benefits, though ongoing recall and quality-related costs remain a factor.
Upgraded 2026 Earnings Guidance After Softer Q2 Might Change The Case For Investing In ICU Medical (ICUI)
ICU Medical (ICUI) reported modest sales growth but softer earnings in Q2 2026, though its six-month net income more than doubled year-over-year. The company has upgraded its full-year 2026 GAAP net income and diluted EPS guidance, suggesting improving profitability and operational efficiencies despite ongoing product recalls and regulatory remediation efforts. This updated guidance strengthens the investment narrative, with community fair value estimates clustering around $191.50 per share.
ICU Medical, Inc. (NASDAQ:ICUI) Given Average Rating of "Moderate Buy" by Brokerages
ICU Medical, Inc. (NASDAQ:ICUI) has received a "Moderate Buy" consensus rating from nine analysts, with an average 12-month price target of $192.80. The company recently surpassed quarterly earnings and revenue expectations, reporting $2.37 EPS on $547.88 million in revenue, and provided fiscal 2026 EPS guidance of $8.60-$9.00. Despite recent insider share sales, institutional investors hold a significant 96.1% stake in the company.
Q1 2026 ICU Medical Inc Earnings Call Transcript
This article provides the edited transcript of ICU Medical Inc.'s Q1 2026 earnings call, which took place on May 7, 2026. The call began with an introduction from an unidentifiable speaker, followed by Thompson from ICR who welcomed participants to discuss the financial results. The transcript also mentions upcoming earnings calls and provides financial data for ICU Medical Inc.
The 5 Most Interesting Analyst Questions From ICU Medical’s Q2 Earnings Call
ICU Medical (ICUI) reported strong Q2 2026 results, beating analyst estimates for revenue, EPS, and EBITDA, with growth driven by Infusion Systems and Consumables. The article highlights five key analyst questions from the earnings call, focusing on the durability of growth, SKU rationalization, gross margin expansion, and tariff refunds. Management's responses indicated continued organic growth, stabilization in Vital Care, and ongoing benefits from operational efficiencies.
Fuller & Thaler boosts disclosure of 5.19% ICU Medical (ICUI) ownership stake
Fuller & Thaler Asset Management, Inc. has filed an amended Schedule 13G, disclosing a 5.19% beneficial ownership stake in ICU Medical (ICUI). The firm holds 1,298,126.96 shares, with sole voting power over 1,276,819.96 shares and sole dispositive power over all 1,298,126.96 shares. The filing, signed by Chief Compliance Officer Hanna Zanoni, indicates a passive investment intent.
ICU Medical (ICUI) Insider Sells 5,417 Shares: VP, GM-Infusion Capital Daniel Woolson Reduces Stake
Daniel Woolson, VP, GM-Infusion Capital at ICU Medical Inc (ICUI), sold 5,417 shares of the company on August 13, 2026, bringing his total ownership to 17,062 shares. This transaction is part of a trend where insiders at ICU Medical have generally been selling more shares than buying over the past year. The company's stock is considered "Significantly Overvalued" by GuruFocus's GF Value, trading at $181.33 with a GF Value of $120.57, and exhibits high valuation multiples compared to industry norms.
Sell Alert: Daniel Woolson Cashes Out $982K In ICU Medical Stock
Daniel Woolson, VP at ICU Medical (NASDAQ: ICUI), recently sold 5,417 shares of the company's stock for a total transaction value of $982,264, as disclosed in an SEC filing. This insider transaction occurred on August 13, leading to a slight dip in ICU Medical's shares. The article also provides an overview of ICU Medical's financial performance, including its revenue growth, profitability indicators, debt management, and valuation metrics.
ICU Medical (ICUI) investor to sell 5,417 shares worth $982K on NASDAQ
ICU Medical shareholder Daniel Woolson plans to sell 5,417 shares of common stock, valued at $982,264.61, on NASDAQ by August 13, 2026. This sale follows a previous transaction three months prior where Woolson sold 2,123 shares for $280,684.80. The shares originate from various performance stock units and restricted stock vesting plans.
ICU Medical VP Daniel Woolson sells $982,264 in stock
ICU Medical VP Daniel Woolson sold 5,417 shares of company stock for $982,264 on August 13, 2026. This insider sale comes as ICUI shares are near their 52-week high, with InvestingPro analysis indicating the stock is undervalued. The company recently reported strong second-quarter results, beating analyst expectations and leading Raymond James to raise its price target to $200.
ICU Medical VP Daniel Woolson sells $982,264 in stock
Daniel Woolson, VP, GM-Infusion Capital at ICU Medical Inc. (NASDAQ:ICUI), sold 5,417 shares of the company's common stock for $982,264 on August 13, 2026, at $181.33 per share. This sale occurred as ICUI shares are near their 52-week high, following strong Q2 results where the company beat earnings and revenue expectations and raised its full-year guidance. Raymond James subsequently raised its price target for ICUI to $200 with a Strong Buy rating.
ICU Medical (ICUI) officer Daniel Woolson sells 5,417 shares at $181.33
Daniel Woolson, VP and GM-Infusion Capital at ICU Medical Inc. (ICUI), sold 5,417 shares of common stock at $181.33 per share on August 13, 2026. After this transaction, Woolson directly holds 17,062 shares of ICU Medical common stock. The sale was not conducted under a Rule 10b5-1 trading plan.
Janus Henderson holds 11.1% of ICU Medical (ICUI) common stock via clients
Janus Henderson Group Ltd. has reported a beneficial ownership of 2,781,621 shares of ICU Medical, Inc. common stock, which constitutes 11.1% of the class. These shares are held through various Managed Portfolios where Janus Henderson's affiliated Asset Managers exercise investment and voting discretion, though the economic benefits like dividends and sale proceeds accrue to the Managed Portfolios, not Janus Henderson. No single Managed Portfolio owns more than five percent of ICU Medical's common stock.
ICU Medical Inc (ICUI) Chief Information Officer Ben Sousa Sells 2,250 Shares
ICU Medical Inc's Chief Information Officer, Ben Sousa, sold 2,250 shares of the company's stock for approximately $401,220. This transaction contributes to a trend of insider selling at the company, with 9 sells versus 2 buys over the last year. The stock is currently deemed "Significantly Overvalued" by GuruFocus, trading at $178.32 against an intrinsic value of $120.56.
Renaissance Technologies LLC Lowers Stock Position in ICU Medical, Inc. $ICUI
Renaissance Technologies LLC significantly reduced its stake in ICU Medical, Inc. by 68.8% in the first quarter, selling 24,991 shares and retaining 11,309 shares worth $1.46 million. Despite this reduction, institutional investors collectively own 96.1% of the company, which recently exceeded quarterly earnings and revenue expectations. Analysts maintain a "Moderate Buy" rating with an average price target of $192.80, even as company insiders have sold shares totaling approximately $2.1 million.
Bank of America Corp DE Boosts Stock Holdings in ICU Medical, Inc. $ICUI
Bank of America Corp DE significantly increased its stake in ICU Medical, Inc. by 11.2% in the first quarter, now holding 331,739 shares valued at $42.8 million. This comes as ICU Medical exceeded Q2 earnings expectations, reporting EPS of $2.37 and revenue of $547.88 million, leading analysts to raise price targets, with a consensus "Moderate Buy" rating. Despite strong institutional ownership and positive analyst sentiment, several insiders have sold shares totaling over $2.1 million in recent months.
The 5 Most Interesting Analyst Questions From ICU Medical’s Q2 Earnings Call
ICU Medical (ICUI) reported strong Q2 CY2026 results, exceeding analyst expectations for revenue, adjusted EPS, and EBITDA, driven by robust performance in Infusion Systems and Consumables. The article highlights key analyst questions from the earnings call, focusing on the drivers of Infusion Systems growth, SKU rationalization, gross margin expansion, and tariff refunds. Management's responses clarified that growth was due to competitive wins and early installations, with expectations for continued organic growth and stabilization in Vital Care.
Ben Sousa Sells 2,250 Shares of ICU Medical (NASDAQ:ICUI) Stock
Ben Sousa, an insider at ICU Medical (NASDAQ:ICUI), recently sold 2,250 shares of the company's stock for approximately $401,220, reducing his direct ownership by 42.25%. This transaction comes as ICU Medical reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Despite the insider sale and a slight dip in stock price, analysts maintain a "Moderate Buy" rating for ICUI with an average price target of $192.80.
Icu Medical Insider Sold Shares Worth $401,209, According to a Recent SEC Filing
An insider at ICU Medical (ICUI) sold shares valued at $401,209, as disclosed in a recent SEC filing. This transaction occurred on August 12, 2026, adding to previous insider sales announcements for the company. ICU Medical manufactures medical products for infusion therapy, vascular access, and vital care.
ICU Medical (ICUI) CIO Ben Sousa sells 2,250 shares of common stock
ICU Medical Inc./DE's Chief Information Officer, Ben Sousa, reported the sale of 2,250 shares of common stock on August 12, 2026, at a price of $178.3152 per share. This transaction leaves him with 3,076 shares of directly held common stock. The sale was executed in an open market or private transaction and was disclosed via a Form 4 filing.
ICU Medical (ICUI) insider plans to sell 2,250 shares of common stock
An insider at ICU Medical, Inc. (ICUI) plans to sell 2,250 shares of common stock with an aggregate market value of $401,209.20 through Morgan Stanley Smith Barney LLC Executive Financial Services. These shares were acquired via equity compensation events, including restricted stock vesting in 2025 and 2026, and performance stock units in 2026. The Form 144 filing indicates a neutral impact and sentiment regarding this proposed sale.
ICU Medical (ICUI) Director Elisha Finney Sells 378 Shares
ICU Medical (ICUI) Director Elisha Finney sold 378 shares of the company on August 11, 2026, totaling approximately $68,977. This transaction adds to a pattern of consistent insider selling, with Finney having sold 1,663 shares over the past year and no purchases. GuruFocus assesses ICU Medical as significantly overvalued with a GF Value of $120.55 compared to its trading price of $182.48, suggesting caution for investors.
ICU Medical Inc (ICUI) Insider Sell: Christian Voigtlander Disposes of 8,929 Shares
Christian Voigtlander, an insider at ICU Medical Inc (ICUI), recently sold 8,929 shares for approximately $1.63 million, reducing his direct ownership to 37,377 shares. This sale contributes to a trend of more insider selling than buying at ICUI over the past year (8 sells vs. 2 buys). The stock is considered significantly overvalued by GuruFocus's GF Value, trading at $182.93 against an intrinsic value of $120.55, and is also facing trimming by institutional investors.
Icu medical director Elisha Finney sells $68,978 in stock
Elisha W. Finney, a director at ICU Medical Inc./DE (NASDAQ:ICUI), sold 378 shares of common stock for $68,978 on August 11, 2026. This transaction occurred as the stock neared its 52-week high, having returned 68% over the past year. Despite the sale, Finney still directly holds 4,871 shares, while InvestingPro analysis suggests the stock is currently overvalued.
Icu medical COO Christian Voigtlander sells $1.63m in stock
ICU Medical COO Christian Voigtlander recently sold 8,929 shares of company stock for over $1.63 million, with transactions occurring on August 11, 2026, as the stock trades near its 52-week high. The company has shown strong financial performance, exceeding Q2 2026 expectations and raising its full-year EPS and EBITDA guidance. Raymond James also raised its price target for ICU Medical, citing robust revenue growth.
Insider Selling: ICU Medical (NASDAQ:ICUI) COO Sells $1,633,381.97 in Stock
ICU Medical (NASDAQ:ICUI) COO Christian Voigtlander sold 8,929 shares of the company's stock for over $1.63 million, reducing his stake by 19.28%. This sale occurred after ICU Medical reported strong quarterly earnings, surpassing analyst expectations for both EPS and revenue, while maintaining its fiscal 2026 EPS guidance. The company holds a "Moderate Buy" consensus rating from analysts, with institutional investors owning a significant 96.10% of its stock.
ICU Medical (ICUI) COO sells 8,929 shares in open-market trade
ICU Medical Inc. (ICUI) Chief Operating Officer Christian B. Voigtlander sold 8,929 shares of common stock on August 11, 2026, at a weighted average price of $182.93 per share. This open-market transaction reduced his direct holdings to 37,377 shares. The sale amounted to approximately $1.63 million.
ICU Medical (ICUI) insider plans resale of 378 vested shares
An insider at ICU Medical Inc. (ICUI) plans to sell 378 shares of common stock, valued at $68,978.08, through Morgan Stanley Smith Barney LLC. These shares were acquired on May 13, 2020, as restricted stock vesting for services rendered. The filing indicates 25,007,000 shares of common stock are currently outstanding.
ICU Medical (ICUI) files Form 144 for planned sale of 8,929 shares
ICU Medical, Inc. (ICUI) has filed a Form 144 indicating a planned resale of 8,929 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares, valued at approximately $1,633,403.62, are related to previously exercised options and vesting equity awards, with an approximate sale date of August 11, 2026. This transaction represents a small fraction of the 25,007,038 shares of common stock outstanding.
